GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News:
Vitrolife AB (publ)(STO:VITR) hereby invites analysts, investors, shareholders and journalists to a Capital Markets Day on November 6.
We will talk about Vitrolife’s business, which assists in making many people’s desire to have children a reality. We will give an update on the operative and financial development of the Vitrolife Group and look deeper into the future of the IVF field. There will be an opportunity to visit one of our production facilities and to see how some of our most important products are used.
November 6, 4 pm – 7 pm.
Vitrolife’s headquarters, Gustaf Werners gata 2, 421 32 Västra Frölunda/Gothenburg.
Please inform Anita Ahlqvist that you will attend by email, email@example.com, or by telephone on +46 (0)31–721 80 83, no later than October 24. A light meal will be served, so please inform us of any allergies you may have. There is a limited number of places. For the full program, please visit www.vitrolife.com. The presentations will be held in Swedish.
Gothenburg, October 6, 2014
VITROLIFE AB (publ)
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife (http://www.vitrolife.com/en/Corporate/) is an international medical device Group. Vitrolife Fertility (http://www.vitrolife.com/en/Fertility/) product area develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes
Vitrolife (http://www.vitrolife.com/en/Corporate/) has approximately 240 employees and the company's products are sold in almost 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is listed on NASDAQ OMX Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE13469), Small Cap.
This information was brought to you by Cision http://news.cision.com